Cassiopea Announces Positive Results from Phase III Acne Open-Label Safety Study Evaluating Winlevi® (Clascoterone) Topical Cream for Treatment up to 1 Year
Cassiopea SpA, a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products, today announced positive safety and efficacy data for its Phase III open-label safety study (Study 27) evaluating Winlevi® (clascoterone) in acne for a treatment period of up to 1 year.